CoChat

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Open access

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with Lewy bodies. Objectives: The primary outcomes of this study were safety and tolerability; pharmacokinetics and target engagement were secondary, while clinical outcomes were exploratory. Methods: Twelve subjects were randomized into 150 mg ( n = 5) or 300 mg ( n = 7) groups and received Nilotinib orally every day for 24 weeks. Results: This study shows that 150 mg and 300 mg doses of Nilotinib appear to be safe and tolerated in subjects with advanced Parkinson’s disease. Nilotinib is detectable in the cerebrospinal fluid (CSF) and seems to engage the target Abl. Motor and cognitive outcomes suggest a possible beneficial effect on clinical outcomes. The CSF levels of homovanillic acid are significantly increased between baseline and 24 weeks of treatment. Exploratory CSF biomarkers were measured. Conclusions: This small proof-of-concept study lacks a placebo group and participants were not homogenous, resulting in baseline differences between and within groups. This limits the interpretations of the biomarker and clinical data, and any conclusions should be drawn cautiously. Nonetheless, the collective observations suggest that it is warranted to evaluate the safety and efficacy of Nilotinib in larger randomized, double-blind, placebo-controlled trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jpd-160867

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Design and milestones of an open-label, phase I clinical trial to evaluate the safety and efficacy of 150 mg and 300 mg Nilotinib for 24 weeks in patients with Parkinson’s disease (PD) with dementia (PDD) or PD with mild cognitive impairment (PD-MCI) or dementia with Lewy bodies (DLB). Cerebrospinal fluid (CSF), Mini Mental State Examination (MMSE), Abelson (Abl), homovanillic acid (HVA), β-amyloid (Aβ), Scales for Outcomes in Parkinson’s Disease-Cognition (SCOPA-Cog), Neuron Specific Enolase (SNE).
Fig.1 Design and milestones of an open-label, phase I clinical trial to evaluate the safety and efficacy of 150 mg and 300 mg Nilotinib for 24 weeks in patients with Parkinson’s disease (PD) with dementia (PDD) or PD with mild cognitive impairment (PD-MCI) or dementia with Lewy bodies (DLB). Cerebrospinal fluid (CSF), Mini Mental State Examination (MMSE), Abelson (Abl), homovanillic acid (HVA), β-amyloid (Aβ), Scales for Outcomes in Parkinson’s Disease-Cognition (SCOPA-Cog), Neuron Specific Enolase (SNE).CC BY-NC · PubMed Central
Fig.2 Pharmacokinetics and pharmacodynamics. Graph shows Nilotinib levels in (A) plasma, (B) CSF and (C) ratio of CSF: plasma of Nilotinib in a population analysis (N = 33 data points) collected at baseline, 1, 2, 3, 4 or 5hrs after oral administration. Plasma was collected 30 min before CSF. Graph (D) is level of Abl inhibition via de-phosphorylation in the same sample population showing the level of pan-tyrosine phosphorylated Abl (active) in the CSF. (E) is non-compartmental analysis of 150 mg and 300 mg of CSF and plasma Nilotinib. Nilotinib was quantified in reference to 13C Nilotinib standard and biological samples were centrifuged to obtain unbound Nilotinib. Cerebrospinal fluid (CSF), Abelson (Abl). Graph shows absorbance levels (ABS) of pan-tyrosine phosphorylated Abl in the CSF of individual participants at baseline and after oral dosing of Nilotinib in the 150 mg (F) and 300 mg (G) groups.
Fig.2 Pharmacokinetics and pharmacodynamics. Graph shows Nilotinib levels in (A) plasma, (B) CSF and (C) ratio of CSF: plasma of Nilotinib in a population analysis (N = 33 data points) collected at baseline, 1, 2, 3, 4 or 5hrs after oral administration. Plasma was collected 30 min before CSF. Graph (D) is level of Abl inhibition via de-phosphorylation in the same sample population showing the level of pan-tyrosine phosphorylated Abl (active) in the CSF. (E) is non-compartmental analysis of 150 mg and 300 mg of CSF and plasma Nilotinib. Nilotinib was quantified in reference to 13C Nilotinib standard and biological samples were centrifuged to obtain unbound Nilotinib. Cerebrospinal fluid (CSF), Abelson (Abl). Graph shows absorbance levels (ABS) of pan-tyrosine phosphorylated Abl in the CSF of individual participants at baseline and after oral dosing of Nilotinib in the 150 mg (F) and 300 mg (G) groups.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 49 references

Research works printed but not linked: 2

  1. 10.1007/s00109-013-1112-3 · DOI · Paper page
  2. Kang JH, 2013, JAMA Neurol, 70, 1277

Cited by

See all 284

Metadata

Authors
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., Lawler, A., Rogers, S. L., Falconer, R. A., Ahn, J., Li, Z., & Moussa, C.
Affiliations
  • Department of Neurology, National Parkinson’s Foundation Center for Excellence, Translational Neurotherapeutics Program. Movement Disorders Program. MedStar Georgetown Hospital Washington, DC, USA
  • Georgetown University Medical Center (US)
  • MedStar Georgetown University Hospital (US)
Corresponding author
Moussa, Charbel
Venue
Journal of Parkinson’s Disease
Published
2016-06-03
Volume
6
Issue
3
Pages
503-517
ISSN
  • 1877-7171 (ISSN-L)
  • 1877-718X
OpenAlex
W2462137239
Cited by
265
References
49
Citations by year
2026: 14 · 2025: 12 · 2024: 20 · 2023: 23 · 2022: 37 · 2021: 34 · 2020: 32 · 2019: 38 · 2018: 30 · 2017: 17 · 2016: 7
FWCI
23.04
Type
journal article
Language
en
Open access
Locations
  • Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Health and Human Services (UL1RR031975)
  • Georgia Clinical and Translational Science Alliance
  • National Institutes of Health (UL1TR001409, UL1TR000101)
  • National Center for Research Resources (UL1RR031975)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
nilotinib, Parkinson's disease, dementia with Lewy bodies, ABL tyrosine kinase inhibitors, cerebrospinal fluid pharmacokinetics, target engagement, homovanillic acid, cerebrospinal fluid biomarkers, drug safety and tolerability
MeSH terms
Dementia, Follow-Up Studies, Humans, Parkinson Disease, Pyrimidines, Outcome Assessment, Health Care, Lewy Body Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies. https://app.cochat.ai/papers/10.3233/jpd-160867
The paper
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., Lawler, A., Rogers, S. L., Falconer, R. A., Ahn, J., Li, Z., & Moussa, C. (2016). Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-160867

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.